低剂量甲氨蝶呤联用头孢曲松致严重中性粒细胞减少两例
本文报告2例炎症性关节炎患者在接受头孢曲松治疗关节感染期间恢复口服低剂量甲氨蝶呤后出现严重中性粒细胞减少,提示两药可能存在相互作用。头孢曲松部分经肾脏有机阴离子转运体清除,可能与甲氨蝶呤在肾小管竞争清除,临床联用时应密切监测中性粒细胞。
要点
- 低剂量甲氨蝶呤联用头孢曲松可能因肾小管清除竞争导致中性粒细胞减少。
- 感染治疗期间恢复甲氨蝶呤需考虑药物相互作用及对愈合的影响。
- 联用期间应密切监测血常规,警惕严重中性粒细胞减少。
核心结论
- 2例炎症性关节炎患者在接受头孢曲松治疗关节感染期间恢复口服低剂量甲氨蝶呤后出现严重中性粒细胞减少。
研究设计与样本
- 病例报告,描述2例可能由甲氨蝶呤与头孢曲松相互作用导致严重中性粒细胞减少的病例。
主要发现
- 2例患者均在头孢曲松治疗关节感染期间恢复口服甲氨蝶呤后发生严重中性粒细胞减少。
- 头孢曲松部分经肾脏有机阴离子转运体清除,可能与甲氨蝶呤在肾小管发生清除竞争。
临床怎么用
- 临床医生联用甲氨蝶呤与头孢曲松时应知晓中性粒细胞减少的潜在风险并密切监测患者。
- 感染治疗期间是否继续甲氨蝶呤需权衡药物相互作用及对愈合过程的影响。
局限性
- 仅为2例病例报告,无法确立因果关系或量化风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are limited data on the effect of ceftriaxone on methotrexate clearance, with results of some studies indicating altered methotrexate pharmacokinetics with the administration of ceftriaxone. We describe 2 possible cases demonstrating an interaction between methotrexate and ceftriaxone, resulting in profound neutropenia. SUMMARY: The decision to continue methotrexate therapy in the setting of surgery or during treatment of an active infection continues to be a topic of debate due to perceived negative effects on the healing process. Methotrexate is typically administered at a lower dose for inflammatory arthritis than for hematologic indications, thus having less immunosuppression potential. However, if methotrexate is continued during treatment of infection, drug interactions along with effects on the healing process should be considered. Ceftriaxone is commonly considered safe for long-term therapy due to its favorable adverse effect and drug interaction profile. Ceftriaxone is partially eliminated via organic anion transporters in the kidneys, leading to potential competition with methotrexate clearance in the renal tubules. Clinicians using these drugs concurrently should be aware of the potential for development of neutropenia and monitor patients receiving this combination closely. CONCLUSION: Two patients receiving ceftriaxone therapy in the setting of a joint infection developed profound neutropenia after resuming oral methotrexate therapy for inflammatory arthritis.
引用
- Bubik RJ, Osmon DR, Oravec CP, et al. Two cases of severe neutropenia in patients on low-dose methotrexate and ceftriaxone. Am J Health Syst Pharm. 2019. PMID: 31361811. doi:10.1093/ajhp/zxz057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。